$CIHN The Integrative Stem Cell Institute is conducting a series of open-label, non-randomized, patient sponsored clinical trials to measure the effectiveness and safety of an integrative medical approach that combines autologous adipose derived mesenchymal cells or bone marrow derived mesenchymal and hematopoietic cells with other preconditioning medical therapies (such as parenteral cellular activation, hyperbaric oxygen therapy and physical therapy), when indicated.